Page 11 - Pharma Sector

Why is Jubilant Pharmova share price buzzing in an overall weak market?

Jubilant Pharmova shares rose after its board approved the slump sale of its API business to wholly-owned subsidiary, Jubilant Biosys.

Bharat Biotech, GSK partner to develop vaccine for Shigella diarrhoea

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added. "With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said. As part of this agreement, Bharat Biotech will lead the further development of ...

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Marksans Pharma shares surge 5% after block trades; details here

Marksans Pharma shares rose 5 per cent after 10.27 million shares changed hands via multiple pre-market block trades

Advent to invest $175 million in animal health drugmaker Felix Pharma

The deal, which includes both primary and secondary transactions, positions Felix to accelerate its global ambitions as a differentiated player in the nascent but expanding companion animal generics

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

AstraZeneca Pharma Q4 FY25 net profit jumps 48% to Rs 58.25 crore

Q4 net profit rises 48% to Rs 58.25 crore; revenue up 25.3% on strong growth across therapeutic areas, with oncology revenue up over 31% and record full-year sales

Here's why Natco Pharma share price is buzzing in trade on Thursday, May 29

Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

Statsguru: Will most-favoured-nation pricing alter India-US pharma ties?

Nearly 35 per cent of India's pharma exports went to the US in FY25, breaching the $10 billion mark. Such exports have more than doubled since FY18

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details

Sun Pharma Q4 results date: Sun Pharma is scheduled to announce its fourth quarter results on Thursday, May 22, 2025

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

Dr Reddy's Q4 results preview: Analysts eye 18% jump in PAT; check details

Dr Reddy's Labs Q4 results 2025 date: Dr Reddy's Laboratories is scheduled to announce its fourth quarter (Q4FY25) results on Friday, May 9, 2025

Insulin's century-old legacy still stands tall amid new diabetes drugs

Despite the rise of GLP-1s and oral therapies, insulin remains vital for millions, particularly those with type 1 diabetes and other insulin-dependent conditions

Trump targets foreign drugs: Tariffs in 2 weeks, begins US mfg push

US President Trump has signed executive orders to speed up drug approvals and pharma infrastructure construction in the US

Akums secures patent for dual-action nausea drug for pregnant women

Akums receives DCGI approval for a dual-release Doxylamine-Pyridoxine tablet designed to relieve nausea and vomiting in pregnancy with reduced dosing frequency